Cassava Sciences (SAVA) announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. “I am thrilled to expand Cassava’s leadership team and welcome Freda Nassif as Chief Commercial Officer. She joins our company at a critical time, ahead of the release of topline results from RETHINK-ALZ, our first Phase 3 trial for simufilam, expected by the end of 2024, and potential product launch,” said Rick Barry, President and Chief Executive Officer. “Freda brings to Cassava a proven track record of successfully developing and implementing effective commercial strategies for innovative medicines. Pending positive simufilam Phase 3 results and FDA approval, we believe Freda’s extensive expertise will be invaluable to the development of a robust commercial plan. She will play a key role in helping to realize our ambitious goal of reimagining the treatment possibilities for Alzheimer’s disease.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAVA:
- Cassava Sciences call volume above normal and directionally bullish
- Cassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress
- Largest borrow rate increases among liquid names
- Cassava Sciences reports Q3 EPS (58c) vs. (61c) last year
- Cassava Sciences sees 2H24 net cash use $40M-$50M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
